Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for
